[HTML][HTML] Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase
HM El Sahly, LR Baden, B Essink… - … England Journal of …, 2021 - Mass Medical Soc
Background At interim analysis in a phase 3, observer-blinded, placebo-controlled clinical
trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease …
trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease …
[HTML][HTML] Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine
LR Baden, HM El Sahly, B Essink… - New England journal …, 2021 - Mass Medical Soc
Background Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to
protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid …
protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid …
[HTML][HTML] Real-world effectiveness of the mRNA-1273 vaccine against COVID-19: Interim results from a prospective observational cohort study
KJ Bruxvoort, LS Sy, L Qian, BK Ackerson… - The Lancet Regional …, 2022 - thelancet.com
Background Phase 3 trials found mRNA-1273 was highly effective in preventing COVID-19.
We conducted a prospective cohort study at Kaiser Permanente Southern California (KPSC) …
We conducted a prospective cohort study at Kaiser Permanente Southern California (KPSC) …
[HTML][HTML] A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine
L Chu, R McPhee, W Huang, H Bennett, R Pajon… - Vaccine, 2021 - Elsevier
Background Vaccines are urgently needed to prevent the global spread of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). We assessed the safety and …
respiratory syndrome coronavirus 2 (SARS-CoV-2). We assessed the safety and …
[HTML][HTML] An mRNA vaccine against SARS-CoV-2—preliminary report
LA Jackson, EJ Anderson, NG Rouphael… - New England journal …, 2020 - Mass Medical Soc
Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged
in late 2019 and spread globally, prompting an international effort to accelerate …
in late 2019 and spread globally, prompting an international effort to accelerate …
[HTML][HTML] Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents
K Ali, G Berman, H Zhou, W Deng… - … England Journal of …, 2021 - Mass Medical Soc
Background The incidence of coronavirus disease 2019 (Covid-19) among adolescents
between 12 and 17 years of age was approximately 900 per 100,000 population from April 1 …
between 12 and 17 years of age was approximately 900 per 100,000 population from April 1 …
[HTML][HTML] Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial
The mRNA-1273 vaccine for coronavirus disease 2019 (COVID-19) demonstrated 93.2%
efficacy in reduction of symptomatic severe acute respiratory syndrome coronavirus 2 (SARS …
efficacy in reduction of symptomatic severe acute respiratory syndrome coronavirus 2 (SARS …
[HTML][HTML] Evaluation of mRNA-1273 Covid-19 vaccine in children 6 to 11 years of age
CB Creech, E Anderson, V Berthaud… - … England Journal of …, 2022 - Mass Medical Soc
Background Vaccination of children to prevent coronavirus disease 2019 (Covid-19) is an
urgent public health need. The safety, immunogenicity, and efficacy of the mRNA-1273 …
urgent public health need. The safety, immunogenicity, and efficacy of the mRNA-1273 …
[HTML][HTML] Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults
EJ Anderson, NG Rouphael, AT Widge… - … England Journal of …, 2020 - Mass Medical Soc
Background Testing of vaccine candidates to prevent infection with severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) in an older population is important, since increased …
syndrome coronavirus 2 (SARS-CoV-2) in an older population is important, since increased …
[HTML][HTML] Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial
L Chu, K Vrbicky, D Montefiori, W Huang… - Nature medicine, 2022 - nature.com
Rising breakthrough infections of severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) in previously immunized individuals have raised concerns for the need for a booster …
CoV-2) in previously immunized individuals have raised concerns for the need for a booster …